Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02615249 · ClinicalTrials.gov registry record · Phase 2
Clinical Evaluation of Metal Panel Allergens: Dose Response Study
A Phase 2 study, sponsored by Allerderm.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT02615249 is a Phase 2 study that has completed, run by Allerderm. The registered enrollment target is 122 participants.
The verdict
NCT02615249, a Phase 2 study, has completed, sponsored by Allerderm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
48-hour application of metal allergen patches to test for potential allergic responses.
Interventions
- BIOLOGICAL Metal Allergen Epicutaneous Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2016-12-05 |
| Est. Completion | 2019-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02615249
The ClinicalTrials.gov registry entry for NCT02615249 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allerderm, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metal Allergen Epicutaneous Patch is the first listed.
NCT02615249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02615249 about?
NCT02615249 is a clinical study titled "Clinical Evaluation of Metal Panel Allergens: Dose Response Study". 48-hour application of metal allergen patches to test for potential allergic responses.
What is the current status of trial NCT02615249?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2016-12-05. Estimated completion is 2019-07-15.
What interventions are being tested in trial NCT02615249?
The interventions under investigation include: Metal Allergen Epicutaneous Patch (BIOLOGICAL).
Who is sponsoring clinical trial NCT02615249?
This trial is sponsored by Allerderm, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.